EP3952840A4 - Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs - Google Patents
Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs Download PDFInfo
- Publication number
- EP3952840A4 EP3952840A4 EP19924315.5A EP19924315A EP3952840A4 EP 3952840 A4 EP3952840 A4 EP 3952840A4 EP 19924315 A EP19924315 A EP 19924315A EP 3952840 A4 EP3952840 A4 EP 3952840A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- behavioral
- methods
- pharmaceutical compositions
- cognitive disorders
- treating mental
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/027293 WO2020209872A1 (fr) | 2019-04-12 | 2019-04-12 | Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3952840A1 EP3952840A1 (fr) | 2022-02-16 |
EP3952840A4 true EP3952840A4 (fr) | 2022-11-23 |
Family
ID=72751206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19924315.5A Pending EP3952840A4 (fr) | 2019-04-12 | 2019-04-12 | Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3952840A4 (fr) |
JP (1) | JP7365426B2 (fr) |
CN (1) | CN113939276A (fr) |
AU (1) | AU2019445048A1 (fr) |
CA (1) | CA3136633A1 (fr) |
WO (1) | WO2020209872A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
EP3962488A4 (fr) * | 2019-04-30 | 2022-12-14 | La Pharma Tech Inc. | Procédé de traitement de troubles mentaux, comportementaux et cognitifs |
US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070104884A (ko) * | 2004-11-24 | 2007-10-29 | 메드포인트 헬쓰케어 인크. | 아젤라스틴을 포함하는 조성물 및 이의 사용 방법 |
WO2014018563A2 (fr) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Procédés pour le traitement du cancer |
US10548855B2 (en) * | 2016-10-28 | 2020-02-04 | Chase Pharmaceuticals Corporation | Memantine combinations and use |
JP7198575B2 (ja) | 2017-07-11 | 2023-01-04 | キョーリンリメディオ株式会社 | メマンチン塩酸塩含有口腔内崩壊錠 |
-
2019
- 2019-04-12 JP JP2021556914A patent/JP7365426B2/ja active Active
- 2019-04-12 CA CA3136633A patent/CA3136633A1/fr active Pending
- 2019-04-12 AU AU2019445048A patent/AU2019445048A1/en not_active Abandoned
- 2019-04-12 WO PCT/US2019/027293 patent/WO2020209872A1/fr unknown
- 2019-04-12 EP EP19924315.5A patent/EP3952840A4/fr active Pending
- 2019-04-12 CN CN201980095322.XA patent/CN113939276A/zh active Pending
Non-Patent Citations (2)
Title |
---|
AIKO HATAKEYAMA ET AL: "AZELASTINE HYDROCHLORIDE ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND ACTIVITIES OF DAILY LIVING IN DEMENTIA PATIENTS", GERIATR. GERONTOL. INT,, vol. 8, 1 January 2008 (2008-01-01), pages 59 - 61, XP002798078 * |
TARIOT PIERRE N ET AL: "MEMANTINE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER DISEASE ALREADY RECEIVING DONEPEZIL. A RANDOMIZED CONTROLLED TRIAL", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 291, no. 3, 21 January 2004 (2004-01-21), pages 317 - 324, XP009075923, ISSN: 0098-7484, DOI: 10.1001/JAMA.291.3.317 * |
Also Published As
Publication number | Publication date |
---|---|
JP2022535644A (ja) | 2022-08-10 |
AU2019445048A1 (en) | 2021-12-02 |
CA3136633A1 (fr) | 2020-10-15 |
WO2020209872A1 (fr) | 2020-10-15 |
CN113939276A (zh) | 2022-01-14 |
EP3952840A1 (fr) | 2022-02-16 |
JP7365426B2 (ja) | 2023-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3952840A4 (fr) | Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs | |
EP3973586A4 (fr) | Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs | |
EP3351616A4 (fr) | Nouveau lactobacillus et composition pour prévenir, atténuer ou traiter des maladies cérébrales dégénératives ou des troubles de la fonction cognitive | |
EP3931189A4 (fr) | Azépino-indoles et autres hétérocycles pour traiter des troubles du cerveau | |
EP3934652A4 (fr) | Composés, compositions et procédés pour le traitement d'une maladie | |
EP3962488A4 (fr) | Procédé de traitement de troubles mentaux, comportementaux et cognitifs | |
EP3906043A4 (fr) | Procédés et compositions pour le traitement de la maladie de fabry | |
EP3681477A4 (fr) | Méthode et composition améliorée pour le traitement d'états pathologiques, de maladies ou de troubles sensibles aux triterpènes | |
EP3858353A4 (fr) | Composition pharmaceutique pour prévenir et traiter la nitm et utilisation pharmaceutique associée | |
EP3492096A4 (fr) | Composition pharmaceutique pour le traitement de maladies oculaires, contenant une protéine cas9 et un arn guide | |
EP3818085A4 (fr) | Compositions et leurs utilisations pour traiter une maladie ou un état pathologique | |
EP3570670A4 (fr) | Compositions et procédés de traitement de maladies et de troubles du stockage lysosomial | |
EP3979985A4 (fr) | Compositions et méthodes pour traiter des troubles du système nerveux central | |
EP3922264A4 (fr) | Composition pharmaceutique permettant la prévention, l'amélioration ou le traitement de maladies de la peau | |
EP3943107A4 (fr) | Composition pour prévenir ou traiter une maladie du cerveau et du système nerveux | |
EP3934646A4 (fr) | Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires | |
EP3755319A4 (fr) | Composés et compositions pour le traitement de troubles musculaires | |
EP4034109A4 (fr) | Méthode et composition pour le traitement d'une maladie | |
EP3636281A4 (fr) | Méthode de traitement de la dépression, et composition pharmaceutique | |
EP3558281A4 (fr) | Traitement de troubles mentaux, du mouvement et du comportement | |
EP3600324A4 (fr) | Composés et compositions pour le traitement de troubles oculaires | |
EP4043012A4 (fr) | Médicament pour le traitement de maladies artérielles et son utilisation | |
EP3946433A4 (fr) | Compositions, dispositifs et méthodes de traitement de la maladie de fabry | |
EP3820477A4 (fr) | Composés, compositions et procédés pour le traitement d'une maladie | |
EP3844168A4 (fr) | Préparations médicamenteuses combinées pour le traitement de patients atteints d'une maladie cardiovasculaire et d'états pathologiques associés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211111 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20221024 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20221018BHEP Ipc: A61K 47/00 20060101ALI20221018BHEP Ipc: A61K 31/495 20060101ALI20221018BHEP Ipc: A61K 31/55 20060101ALI20221018BHEP Ipc: A61K 31/13 20060101ALI20221018BHEP Ipc: A61K 9/48 20060101ALI20221018BHEP Ipc: A61K 9/20 20060101ALI20221018BHEP Ipc: A61K 9/14 20060101ALI20221018BHEP Ipc: A61K 9/10 20060101ALI20221018BHEP Ipc: A61K 9/08 20060101AFI20221018BHEP |